Drug Trial Radar · NCT01743027
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Last checked: Nov 19, 2026Latest source record: Aug 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
902
Actual
Start
Jan 2013
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
Conditions
- Allergic Conjunctivitis
Interventions
AL-4943A ophthalmic solutionDrug
Olopatadine hydrochloride ophthalmic solution, 0.2%Drug
Olopatadine hydrochloride ophthalmic solution, 0.1%Drug
AL-4943A ophthalmic solution vehicleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Ocular Itching at Onset of ActionTime frame: Day 14 (3, 5, and 7 minutes post-CAC)
- Mean Ocular Itching at 24 Hours Duration of ActionTime frame: Day 1 (3, 5, and 7 minutes post-CAC)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.